M&A Deal Summary

Cumberland Pharmaceuticals Acquires Theravance Biopharma - VIBATIV

On November 6, 2018, Cumberland Pharmaceuticals acquired life science company Theravance Biopharma - VIBATIV from Theravance Biopharma for 20M USD

Acquisition Highlights
  • This is Cumberland Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Cumberland Pharmaceuticals’ largest (disclosed) transaction.
  • This is Cumberland Pharmaceuticals’ 1st transaction in the United States.
  • This is Cumberland Pharmaceuticals’ 1st transaction in California.

M&A Deal Summary
Date 2018-11-06
Target Theravance Biopharma - VIBATIV
Sector Life Science
Buyer(s) Cumberland Pharmaceuticals
Sellers(s) Theravance Biopharma
Deal Type Divestiture
Deal Value 20M USD

Target

Theravance Biopharma - VIBATIV

South San Francisco, California, United States
Theravance Biopharma, Inc. - VIBATIV is patented, FDA approved anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin & skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Cumberland Pharmaceuticals

Nashville, Tennessee, United States
Category Company
Founded 1999
Sector Life Science
Employees91
Revenue 40M USD (2023)
DESCRIPTION

Cumberland Pharmaceuticals is a pharmaceutical company that acquires and develops branded prescription products primarily in the gastroenterology, critical care and infection control areas. Cumberland Pharmaceuticals was founded in 1999 and is based in Nashville, Tennessee.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2018) 1 of 1
Size (of disclosed) 1 of 1

Seller(S) 1

SELLER

Theravance Biopharma

George Town, Cayman Islands
Category Company
Founded 2013
Sector Life Science
Employees99
Revenue 57M USD (2023)
DESCRIPTION

Theravance Biopharma is a biopharmaceutical company with one approved product, VIBATIV® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance Biopharma was founded in 2013 and is based in George Town, Caymen Islands.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2018) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal